Baird Capital, the private investment arm of Robert W. Baird & Co., has raised $185 million for its oversubscribed fourth venture capital fund, sweeping past its $150 million target. Fund IV’s LP base includes numerous institutions, foundations and family offices. So far, the fund has made investments in Catalyze, emids, Integrated Diagnostics, NeuMoDx Molecular and WordStream.
CHICAGO, Nov. 18, 2014 – Baird Capital, the direct private investment arm of Robert W. Baird & Co. (Baird), announced the final close of its fourth Venture Capital fund with a total of $185 million in committed capital, exceeding its initial target of $150 million and the size of its previous fund. Fund IV was oversubscribed, anchored by support from numerous institutions, foundations and family offices.
“With our experienced team and disciplined investment strategy, we will continue striving to generate strong returns for our investors,” said Gordon Pan, Managing Partner of Baird Capital. “We are very happy to have the continued support of our existing investors as well as the backing of many new limited partners.”
Baird Capital’s Venture Capital team is led by Pan and Investment Partners Michael Liang, Ph.D., Jim Pavlik, Benedict Rocchio and Principal Nicole Walker, as well as Venture Partners David Gregorka, Don Layden and Fred Robertson.
To date Fund IV has already invested in five companies: Catalyze, emids, Integrated Diagnostics, NeuMoDx Molecular, and WordStream.
Baird Capital’s Venture Capital team partners with entrepreneurs to build innovative, high-growth companies within the technology-enabled services and healthcare sectors. Committing $10 million to $15 million in equity over the life of an investment, the Venture Capital team looks to partner with companies with strong and experienced management teams, capital efficient business models, and differentiated products or services that address large market opportunities.
About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Baird Capital’s Venture Capital team invests in early and growth stage technology-enabled services and healthcare companies. Having invested in more than 280 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit www.BairdCapital.com.